

**Leroy A. Richardson,**  
*Chief, Information Collection Review Office,  
 Office of Scientific Integrity, Office of the  
 Associate Director for Science, Office of the  
 Director, Centers for Disease Control and  
 Prevention.*

[FR Doc. 2015-10286 Filed 5-1-15; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND  
 HUMAN SERVICES**

**Administration for Children and  
 Families**

**Submission for OMB Review;  
 Comment Request**

*Title:* Child Care Development Fund,  
 CCDF; Reporting Improper Payments;  
 Instructions for States.

*OMB No.:* 0970-0323.

*Description:* Section 2 of the Improper  
 Payments Act of 2002 provides for  
 estimates and reports of improper  
 payments by Federal agencies. Subpart  
 K of 45 CFR, part 98 will require States  
 to prepare and submit a report of errors

occurring in the administration of CCDF  
 grant funds once every three years.

The Office of Child Care (OCC) is  
 completing the third 3-year cycle of case  
 record reviews to meet the requirements  
 for reporting under IPIA. The current  
 forms and instructions expire  
 September 30, 2015. OCC is submitting  
 the information collection for renewal  
 clearance with minor changes.  
 Responders will now have additional  
 guidance and clarification in the  
 instructions and errors have been  
 corrected. New language incorporates  
 requirements from the 2014 Child Care  
 and Development Fund Block Grant Act  
 passed in November 2014.

*Respondents:* State grantees, the  
 District of Columbia, and Puerto Rico

**ANNUAL BURDEN ESTIMATES**

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Sampling Decisions and Fieldwork Preparation Plan .....	17	1	106	1,802
Record Review Worksheet .....	17	276	6.33	29,700.36
State Improper Authorizations for Payment Report .....	17	1	639	10,863
Corrective Action Plan .....	8	1	156	1,248

*Estimated Total Annual Burden  
 Hours:* 43,613.36.

*Additional Information:* Copies of the  
 proposed collection may be obtained by  
 writing to the Administration for  
 Children and Families, Office of  
 Planning, Research and Evaluation, 370  
 L'Enfant Promenade SW., Washington,  
 DC 20447, Attn: ACF Reports Clearance  
 Officer. All requests should be  
 identified by the title of the information  
 collection. Email address:  
[infocollection@acf.hhs.gov](mailto:infocollection@acf.hhs.gov).

*OMB Comment:* OMB is required to  
 make a decision concerning the  
 collection of information between 30  
 and 60 days after publication of this  
 document in the **Federal Register**.  
 Therefore, a comment is best assured of  
 having its full effect if OMB receives it  
 within 30 days of publication. Written  
 comments and recommendations for the  
 proposed information collection should  
 be sent directly to the following: Office  
 of Management and Budget, Paperwork  
 Reduction Project, Email: [OIRA\\_](mailto:OIRA_SUBMISSION@OMB.EOP.GOV)  
[SUBMISSION@OMB.EOP.GOV](mailto:SUBMISSION@OMB.EOP.GOV). Attn:  
 Desk Officer for the Administration for  
 Children and Families.

**Robert Sargis,**

*Reports Clearance Officer.*

[FR Doc. 2015-10296 Filed 5-1-15; 8:45 am]

**BILLING CODE 4184-01-P**

**DEPARTMENT OF HEALTH AND  
 HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA-2013-E-0785]

**Determination of Regulatory Review  
 Period for Purposes of Patent  
 Extension; RELAY THORACIC STENT-  
 GRAFT WITH PLUS DELIVERY  
 SYSTEM**

**AGENCY:** Food and Drug Administration,  
 HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug  
 Administration (FDA) has determined  
 the regulatory review period for the  
 RELAY THORACIC STENT-GRAFT  
 WITH PLUS DELIVERY SYSTEM and is  
 publishing this notice of that  
 determination as required by law. FDA  
 has made the determination because of  
 the submission of an application to the  
 Director of the U.S. Patent and  
 Trademark Office (USPTO), Department  
 of Commerce, for the extension of a  
 patent which claims that medical  
 device.

**ADDRESSES:** Submit electronic  
 comments to [http://](http://www.regulations.gov)  
[www.regulations.gov](http://www.regulations.gov). Submit written  
 petitions (two copies are required) and  
 written comments to the Division of  
 Dockets Management (HFA-305), Food  
 and Drug Administration, 5630 Fishers

Lane, Rm. 1061, Rockville, MD 20852.  
 Submit petitions electronically to [http://](http://www.regulations.gov)  
[www.regulations.gov](http://www.regulations.gov) at Docket No.  
 FDA-2013-S-0610.

**FOR FURTHER INFORMATION CONTACT:**  
 Beverly Friedman, Office of  
 Management, Food and Drug  
 Administration, 10001 New Hampshire  
 Ave., Hillandale Campus, Rm. 3180,  
 Silver Spring, MD 20993, 301-796-  
 7900.

**SUPPLEMENTARY INFORMATION:** The Drug  
 Price Competition and Patent Term  
 Restoration Act of 1984 (Pub. L. 98-417)  
 and the Generic Animal Drug and Patent  
 Term Restoration Act (Pub. L. 100-670)  
 generally provide that a patent may be  
 extended for a period of up to 5 years  
 so long as the patented item (human  
 drug product, animal drug product,  
 medical device, food additive, or color  
 additive) was subject to regulatory  
 review by FDA before the item was  
 marketed. Under these acts, a product's  
 regulatory review period forms the basis  
 for determining the amount of extension  
 an applicant may receive.

A regulatory review period consists of  
 two periods of time: A testing phase and  
 an approval phase. For medical devices,  
 the testing phase begins with a clinical  
 investigation of the device and runs  
 until the approval phase begins. The  
 approval phase starts with the initial  
 submission of an application to market  
 the device and continues until  
 permission to market the device is